Please ensure Javascript is enabled for purposes of website accessibility

Cassava Sciences vs. Biogen

By Taylor Carmichael – Aug 12, 2021 at 5:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Who will emerge victorious in the race to help Alzheimer's patients?

Mighty Biogen (BIIB -4.34%) is a massive biotech, weighing in at $50 billion (market cap). Tiny Cassava Sciences (SAVA -2.89%) is less than one-tenth the size, with a valuation of $4 billion. Both companies are pursuing Alzheimer's drugs.

Alzheimer's is a massive market opportunity -- over $100 billion by some estimates. Biogen recently got its Alzheimer's drug aducanumab approved, even though it failed to beat a placebo and might cause brain bleeds. Cassava's drug, simufilam, is about to enter phase 3 trials later this year.

Which company will ultimately win? Motley Fool editor and analyst Olivia Zitkus and Fool.com writer Taylor Carmichael try to pick the stronger investment for Fools. (But first they have to figure out how to pronounce those drug names.) This Motley Fool Live segment was recorded on July 30.

10 stocks we like better than Biogen
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 9, 2021

 

Taylor Carmichael: One big difference in what Cassava is trying to do is they're not focused on the plaques, the amyloid plaques. This is gene company, they're trying to fix a gene that's broken that you also see in Alzheimer's patients. How do you pronounce it?

Olivia Zitkus: Simufilam.

Taylor Carmichael: That's the drug, but the actual gene is Filamin A?

Olivia Zitkus: Filamin A, yeah.

Taylor Carmichael: I might be mispronouncing it. I don't know how to pronounce it.

Olivia Zitkus: That's OK. That's the risk we run with these biotech and healthcare chats. I looked at a drug name and I'm like, I never said this out loud before. [laughs]

Taylor Carmichael: It's funny because the CEO gave an interview and the interviewer asked him, "Why did you pick such a weird name," and he said, "We didn't pick it, we didn't pick it."

Olivia Zitkus: [laughs]

Taylor Carmichael: They don't actually pick the scientific name for their drug, it's picked for them. Biogen's drug that they put on the market, it's a weird name and I'm like, that's the name you pick? I can't even say it.

Olivia Zitkus: I know. That's the difference between Cassava's drug and Biogen's drug, right? Cassava's drug is a gene therapy and Aduhelm is targeting the amyloid plaque. The other big thing here is that Aduhelm is administered by IV intravenously and simufilam is orally administered in a pill form.

Next video: Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate

10 stocks we like better than Biogen
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 9, 2021

 

Taylor Carmichael owns shares of Cassava Sciences, Inc. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Stock Quote
Biogen
BIIB
$291.90 (-4.34%) $-13.25
Cassava Sciences, Inc. Stock Quote
Cassava Sciences, Inc.
SAVA
$33.91 (-2.89%) $-1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.